Symbols / ABOS Stock $2.67 -4.98% Acumen Pharmaceuticals, Inc.
ABOS (Stock) Chart
About
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 192.81M | Enterprise Value | 117.36M | Income | -121.33M | Sales | — | Book/sh | 1.16 | Cash/sh | 1.62 |
| Dividend Yield | — | Payout | 0.00% | Employees | 60 | IPO | — | P/E | — | Forward P/E | -1.92 |
| PEG | — | P/S | — | P/B | 2.30 | P/C | — | EV/EBITDA | -0.95 | EV/Sales | — |
| Quick Ratio | 3.93 | Current Ratio | 4.07 | Debt/Eq | 44.46 | LT Debt/Eq | — | EPS (ttm) | -2.00 | EPS next Y | -1.39 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-12 | ROA | -42.78% | ROE | -96.20% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 72.21M | Shs Float | 40.72M | Short Float | 1.87% |
| Short Ratio | 1.21 | Short Interest | — | 52W High | 3.60 | 52W Low | 0.96 | Beta | 0.34 | Avg Volume | 904.19K |
| Volume | 297.88K | Target Price | $7.40 | Recom | None | Prev Close | $2.81 | Price | $2.67 | Change | -4.98% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-26 | reit | BTIG | Buy → Buy | $8 |
| 2026-03-16 | main | BTIG | Buy → Buy | $8 |
| 2026-01-27 | main | BTIG | Buy → Buy | $7 |
| 2025-11-18 | main | B of A Securities | Buy → Buy | $8 |
| 2025-08-25 | main | B of A Securities | Buy → Buy | $9 |
| 2025-06-17 | init | Citigroup | — → Buy | $4 |
| 2025-03-28 | main | UBS | Buy → Buy | $4 |
| 2025-03-28 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-15 | main | UBS | Buy → Buy | $6 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-25 | init | Citigroup | — → Buy | $7 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-03-31 | main | UBS | Buy → Buy | $14 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-12-12 | init | Deutsche Bank | — → Buy | $8 |
| 2023-08-09 | reit | Credit Suisse | Outperform → Outperform | $13 |
| 2023-08-09 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-07-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $13 |
- [ARS] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan hu, 23 Apr 2026 20
- Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 30 Mar 2026 07
- Acumen (ABOS) Stock: Strategic Buy or Not (Eye on Rally) 2026-04-22 - Shared Momentum Picks - UBND thành phố Hải Phòng hu, 23 Apr 2026 01
- Acumen (ABOS) Stock: Strategic Buy or Not (Eye on Rally) 2026-04-22 - Alpha Picks - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 01
- Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN hu, 23 Apr 2026 04
- Acumen (NASDAQ: ABOS) seeks approval for major equity plan expansion - Stock Titan hu, 23 Apr 2026 20
- ABOS Acumen reports narrower Q4 2025 loss than consensus estimates, shares rise modestly in today’s trading. - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 23
- $ABOS stock is down 8% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Mar 2026 07
- Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - qz.com Mon, 30 Mar 2026 07
- Acumen Pharmaceuticals, Inc. Common Stock ABOS ) Stock Price Today & Analysis - Gotrade hu, 05 Feb 2026 19
- Should I buy Acumen Pharmaceuticals (ABOS) - Zacks Investment Research Mon, 30 Mar 2026 07
- $ABOS stock is up 21% today. Here's what we see in our data. | ABOS Stock News - Quiver Quantitative Mon, 26 Jan 2026 08
- Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance ue, 31 Mar 2026 07
- Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance Mon, 26 Jan 2026 08
- James B. Murray Jr. discloses 3.61M shares in Acumen Pharmaceuticals (NASDAQ: ABOS) - Stock Titan ue, 07 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
123.83
+8.61%
|
114.02
+86.49%
|
61.14
+35.15%
|
45.24
|
| Research And Development |
|
104.89
+11.82%
|
93.80
+121.65%
|
42.32
+30.77%
|
32.36
|
| Selling General And Administration |
|
18.95
-6.29%
|
20.22
+7.43%
|
18.82
+46.16%
|
12.88
|
| General And Administrative Expense |
|
18.95
-6.29%
|
20.22
+7.43%
|
18.82
+46.16%
|
12.88
|
| Other Gand A |
|
18.95
-6.29%
|
20.22
+7.43%
|
18.82
+46.16%
|
12.88
|
| Total Expenses |
|
123.83
+8.61%
|
114.02
+86.49%
|
61.14
+35.15%
|
45.24
|
| Operating Income |
|
-123.83
-8.61%
|
-114.02
-86.49%
|
-61.14
-35.15%
|
-45.24
|
| Total Operating Income As Reported |
|
-123.83
-8.61%
|
-114.02
-86.49%
|
-61.14
-35.15%
|
-45.24
|
| EBITDA |
|
-116.93
-19.21%
|
-98.08
-90.06%
|
-51.61
-20.89%
|
-42.69
|
| Normalized EBITDA |
|
-116.47
-16.85%
|
-99.67
-98.37%
|
-50.25
-17.71%
|
-42.69
|
| Reconciled Depreciation |
|
0.18
+3.37%
|
0.18
-3.26%
|
0.18
+8.88%
|
0.17
|
| EBIT |
|
-117.11
-19.18%
|
-98.26
-89.73%
|
-51.79
-20.85%
|
-42.86
|
| Total Unusual Items |
|
-0.46
-128.93%
|
1.59
+216.91%
|
-1.36
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-0.46
-128.93%
|
1.59
+216.91%
|
-1.36
|
—
|
| Net Income |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Pretax Income |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Net Non Operating Interest Income Expense |
|
3.22
-68.55%
|
10.25
+0.38%
|
10.21
+326.84%
|
2.39
|
| Interest Expense Non Operating |
|
4.22
+3.83%
|
4.07
+600.17%
|
0.58
|
0.00
|
| Net Interest Income |
|
3.22
-68.55%
|
10.25
+0.38%
|
10.21
+326.84%
|
2.39
|
| Interest Expense |
|
4.22
+3.83%
|
4.07
+600.17%
|
0.58
|
0.00
|
| Interest Income Non Operating |
|
7.45
-47.98%
|
14.32
+32.68%
|
10.79
+351.13%
|
2.39
|
| Interest Income |
|
7.45
-47.98%
|
14.32
+32.68%
|
10.79
+351.13%
|
2.39
|
| Other Income Expense |
|
-0.73
-150.45%
|
1.44
+199.72%
|
-1.44
-13018.18%
|
-0.01
|
| Other Non Operating Income Expenses |
|
-0.27
-76.16%
|
-0.15
-81.93%
|
-0.08
-654.55%
|
-0.01
|
| Gain On Sale Of Security |
|
-0.46
-128.93%
|
1.59
+216.91%
|
-1.36
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Net Income From Continuing Operation Net Minority Interest |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Net Income From Continuing And Discontinued Operation |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Net Income Continuous Operations |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Normalized Income |
|
-120.88
-16.32%
|
-103.92
-103.72%
|
-51.01
-19.03%
|
-42.86
|
| Net Income Common Stockholders |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Diluted EPS |
|
-2.00
-16.96%
|
-1.71
-58.33%
|
-1.08
-1.89%
|
-1.06
|
| Basic EPS |
|
-2.00
-16.96%
|
-1.71
-58.33%
|
-1.08
-1.89%
|
-1.06
|
| Basic Average Shares |
|
60.56
+0.91%
|
60.01
+23.46%
|
48.61
+19.72%
|
40.60
|
| Diluted Average Shares |
|
60.56
+0.91%
|
60.01
+23.46%
|
48.61
+19.72%
|
40.60
|
| Diluted NI Availto Com Stockholders |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
310.12
|
| Current Assets |
|
246.62
|
| Cash Cash Equivalents And Short Term Investments |
|
243.52
|
| Cash And Cash Equivalents |
|
66.89
|
| Other Short Term Investments |
|
176.64
|
| Receivables |
|
0.23
|
| Other Receivables |
|
—
|
| Accrued Interest Receivable |
|
0.23
|
| Prepaid Assets |
|
0.91
|
| Other Current Assets |
|
1.96
|
| Total Non Current Assets |
|
63.51
|
| Net PPE |
|
0.50
|
| Gross PPE |
|
0.50
|
| Other Properties |
|
0.50
|
| Goodwill And Other Intangible Assets |
|
0.17
|
| Other Intangible Assets |
|
0.17
|
| Investments And Advances |
|
62.55
|
| Non Current Prepaid Assets |
|
0.04
|
| Other Non Current Assets |
|
0.24
|
| Total Liabilities Net Minority Interest |
|
43.15
|
| Current Liabilities |
|
12.97
|
| Payables And Accrued Expenses |
|
8.20
|
| Payables |
|
1.38
|
| Accounts Payable |
|
1.38
|
| Current Accrued Expenses |
|
6.82
|
| Employee Benefits |
|
0.00
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.69
|
| Current Debt And Capital Lease Obligation |
|
0.87
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.87
|
| Other Current Liabilities |
|
0.21
|
| Total Non Current Liabilities Net Minority Interest |
|
30.18
|
| Long Term Debt And Capital Lease Obligation |
|
27.62
|
| Long Term Debt |
|
27.34
|
| Long Term Capital Lease Obligation |
|
0.28
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
266.97
|
| Common Stock Equity |
|
266.97
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
57.91
|
| Ordinary Shares Number |
|
57.91
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
489.45
|
| Retained Earnings |
|
-222.80
|
| Gains Losses Not Affecting Retained Earnings |
|
0.31
|
| Other Equity Adjustments |
|
0.31
|
| Total Equity Gross Minority Interest |
|
266.97
|
| Total Capitalization |
|
294.31
|
| Working Capital |
|
233.64
|
| Invested Capital |
|
294.31
|
| Total Debt |
|
28.49
|
| Capital Lease Obligations |
|
1.15
|
| Net Tangible Assets |
|
266.80
|
| Tangible Book Value |
|
266.80
|
| Available For Sale Securities |
|
62.55
|
| Derivative Product Liabilities |
|
2.56
|
| Interest Payable |
|
0.25
|
| Investmentin Financial Assets |
|
62.55
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-115.54
-34.01%
|
-86.22
-100.20%
|
-43.06
-22.50%
|
-35.15
|
| Cash Flow From Continuing Operating Activities |
|
-115.54
-34.01%
|
-86.22
-100.20%
|
-43.06
-22.50%
|
-35.15
|
| Net Income From Continuing Operations |
|
-121.33
-18.57%
|
-102.33
-95.39%
|
-52.37
-22.20%
|
-42.86
|
| Depreciation Amortization Depletion |
|
0.18
+3.37%
|
0.18
-3.26%
|
0.18
+8.88%
|
0.17
|
| Depreciation |
|
0.18
+3.37%
|
0.18
-3.26%
|
0.18
+8.88%
|
0.17
|
| Depreciation And Amortization |
|
0.18
+3.37%
|
0.18
-3.26%
|
0.18
+8.88%
|
0.17
|
| Other Non Cash Items |
|
1.29
-4.59%
|
1.35
+52.71%
|
0.88
|
—
|
| Stock Based Compensation |
|
9.85
+2.25%
|
9.63
+56.79%
|
6.14
+100.75%
|
3.06
|
| Operating Gains Losses |
|
0.40
+123.77%
|
-1.69
-225.06%
|
1.35
|
—
|
| Gain Loss On Investment Securities |
|
0.40
+123.77%
|
-1.69
-225.06%
|
1.35
|
—
|
| Change In Working Capital |
|
-5.12
-143.93%
|
11.65
+201.42%
|
3.87
-3.01%
|
3.99
|
| Change In Receivables |
|
—
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
1.36
+137.25%
|
-3.66
-890.79%
|
-0.37
-121.71%
|
1.70
|
| Change In Payables And Accrued Expense |
|
-6.52
-142.74%
|
15.26
+255.83%
|
4.29
+67.50%
|
2.56
|
| Change In Accrued Expense |
|
-1.43
-112.99%
|
10.99
+141.57%
|
4.55
+126.54%
|
2.01
|
| Change In Payable |
|
-5.09
-219.33%
|
4.27
+1735.63%
|
-0.26
-147.28%
|
0.55
|
| Change In Account Payable |
|
-5.09
-219.33%
|
4.27
+1735.63%
|
-0.26
-147.28%
|
0.55
|
| Change In Other Current Assets |
|
0.04
-45.95%
|
0.07
+205.71%
|
-0.07
+48.91%
|
-0.14
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.02
-235.29%
|
0.02
+112.41%
|
-0.14
|
| Investing Cash Flow |
|
133.93
+178.87%
|
48.03
+127.98%
|
-171.67
-538.10%
|
39.19
|
| Cash Flow From Continuing Investing Activities |
|
133.93
+178.87%
|
48.03
+127.98%
|
-171.67
-538.10%
|
39.19
|
| Net PPE Purchase And Sale |
|
-0.09
-450.00%
|
-0.02
+11.11%
|
-0.02
+88.82%
|
-0.16
|
| Purchase Of PPE |
|
-0.09
-450.00%
|
-0.02
+23.81%
|
-0.02
+86.96%
|
-0.16
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Capital Expenditure |
|
-0.09
-450.00%
|
-0.02
+23.81%
|
-0.02
+86.96%
|
-0.16
|
| Net Investment Purchase And Sale |
|
134.02
+178.96%
|
48.04
+127.99%
|
-171.65
-536.27%
|
39.35
|
| Purchase Of Investment |
|
-38.06
+77.71%
|
-170.73
+31.88%
|
-250.63
-503.73%
|
-41.51
|
| Sale Of Investment |
|
172.08
-21.34%
|
218.77
+177.00%
|
78.98
-2.32%
|
80.86
|
| Financing Cash Flow |
|
-0.03
-100.49%
|
6.93
-95.43%
|
151.75
+3784.13%
|
3.91
|
| Cash Flow From Continuing Financing Activities |
|
-0.03
-100.49%
|
6.93
-95.43%
|
151.75
+3784.13%
|
3.91
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.74
-102.46%
|
30.00
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
30.00
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.74
|
0.00
|
—
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
30.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.74
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-0.74
-102.46%
|
30.00
|
0.00
|
| Net Common Stock Issuance |
|
-0.07
-100.92%
|
7.90
-93.52%
|
121.90
+3114.77%
|
3.79
|
| Common Stock Payments |
|
-0.07
-78.05%
|
-0.04
|
0.00
|
—
|
| Cash Dividends Paid |
|
—
|
0.00
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
-0.07
-78.05%
|
-0.04
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.04
|
0.00
-100.00%
|
0.33
+182.61%
|
0.12
|
| Net Other Financing Charges |
|
—
|
-0.23
+51.68%
|
-0.48
|
—
|
| Changes In Cash |
|
18.36
+158.74%
|
-31.26
+50.37%
|
-62.98
-893.32%
|
7.94
|
| Beginning Cash Position |
|
35.86
-46.57%
|
67.12
-48.41%
|
130.10
+6.50%
|
122.16
|
| End Cash Position |
|
54.22
+51.20%
|
35.86
-46.57%
|
67.12
-48.41%
|
130.10
|
| Free Cash Flow |
|
-115.63
-34.09%
|
-86.23
-100.14%
|
-43.09
-22.01%
|
-35.31
|
| Interest Paid Supplemental Data |
|
2.94
-1.24%
|
2.97
+1659.17%
|
0.17
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-0.81
+83.87%
|
-5.01
-60.69%
|
-3.12
-740.86%
|
0.49
|
| Common Stock Issuance |
|
0.00
-100.00%
|
7.94
-93.49%
|
121.90
+3114.77%
|
3.79
|
| Interest Paid CFF |
|
—
|
0.00
+100.00%
|
-0.48
|
—
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
7.94
-93.49%
|
121.90
+3114.77%
|
3.79
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 42026-03-18 View
- 8-K2026-03-16 View
- 42026-03-10 View
- 42026-03-03 View
- 42026-01-28 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|